# Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Source: https://onco.cc/trials/nct07227298/  
OnCo record `nct07227298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PF-08634404, PF-08046054 in non-small-cell lung cancer and small-cell lung cancer, run by Pfizer, now recruiting.

## Summary

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers is a phase 1/2 interventional study registered as NCT07227298 by Pfizer, with 162 participants planned, started 2026-01-30 and due to reach its primary completion in 2029-03-08. Interventions recorded: PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07227298
- Phase: 1/2
- Setting: AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Sponsor: Pfizer
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT07227298: https://clinicaltrials.gov/study/NCT07227298

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [PF-08046054](https://onco.cc/drugs/pf-08046054/), [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07227298.json